Abstract
Thirty-three patients with multiple myeloma were studied with serial skeletal surveys, serum immunoglobulin levels, and postabsorptive urinary hydroxyproline (Spot-HYPRO) determinations. Twenty receiving chemotherapy were also followed with skeletal surveys in order to evaluate bone response to treatment. A close association was found between skeletal findings and changes in immunoglobulin levels with positive correlation in 71% of the patients. A similar association was found between skeletal disease and Spot-HYPRO level changes in 65%. Five of 12 patients (42%) with partial or complete clinical response to chemotherapy, demonstrated improvement in the appearance of skeletal lesions. Positive correlation between the roentgenographic changes and clinical markers of myeloma as well as therapeutic response, indicates that skeletal surveys are useful and effective in monitoring patients with multiple myeloma.
Similar content being viewed by others
References
Carson CP, Ackerman LC, Maltby JD (1955) Plasma cell myeloma. A clinical, pathologic and roentgenologic review of 90 cases. Am J Clin Pathol 25:849
Chronic Leukemia-Myeloma Task Force, National Cancer Institute (1973) Proposed guidelines for protocol studies —11. Plasma cell myeloma. Cancer Chem Rep (Part 3) 4:145
Dahlin DC (1978) Bone tumors: general aspects and data on 6,221 cases. 3rd edn. Charles C Thomas, Springfield, p 159
Deaton CD, Maxwell KW, Smith RD, Craveling RL (1976) Use of las-R nephelometry in the measurement of serum proteins. Clin Chem 22:1465
Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36:842
Helms CA, Genant HK (1982) Computed tomography in the early detection of skeletal involvement with multiple myeloma. JAMA 248–2886
Himmelfarb E, Sebes J, Robinowitz J (1974) Unusual roentgenographic presentations of multiple myeloma. J Bone Joint Surg [Am] 56:1723
Kricun ME (1985) Red-yellow marrow conversion: its effect on the location of some solitary bone lesions. Skeletal Radiol 14:10
Kyle RA (1975) Multiple myeloma; review of 869 cases. Mayo Clin Proc 50:29
Meszaros WT (1974) The many facets of multiple myeloma. Semin Roentgenol 9:219
Mundy GD, Raisz LG, Cooper RA, Schechter GP, Salmon SE (1974) Evidence for the secretion of an osteoclast-stimulating factor in myeloma. N Engl J Med 291:1042
Niell HB, Neely CL, Palmieri GM (1981) The postabsorptive urinary hydroxyproline (Spot-HYPRO) in patients with multiple myeloma. Cancer 48:783
Niell HB, Palmieri GM, Neely CL, Maxwell TA, Hopkins SC, Soloway MS (1983) Total dialyzable and nondializable postabsorptive hydroxyproline. Arch Intern Med 143:1925
Niell HB, Neely CL, Palmieri GM, McDonald W (1983) The postabsorptive hydroxyproline in the long-term evolution of patients with breast cancer. Cancer 52:1442
Prockop DJ, Undenfriend S (1960) A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem 1:228
Rodrigues LH, Einkelstein JB, Schullenberger CC, Alexanian R (1972) Bone healing in multiple myeloma with melphalan chemotherapy. Ann Intern Med 76–551
Rundels RW, Reeves RJ (1950) Multiple myeloma II. Roentgen appearance and effect of urethane therapy on skeletal disease. AJR 64:799
Schreiman JS, McLeod RA, Kyel RA, Beabout JW (1985) Multiple myeloma: evaluation by CT. Radiology 154:483
Uehlinger E (1976) Case report 1. Skeletal Radiol 1:55
Waldenstrom J (1964) Melphalan therapy in myelomatosis. Br Med J 1:859
Woolfenden JM, Pitt MJ, Durie BGM, Moon TE (1980) Comparision of bone scintigraphy and radiography in multiple myeloma. Radiology 134:723
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sebes, J.I., Niell, H.B., Palmieri, G.M.A. et al. Skeletal surveys in multiple myeloma. Skeletal Radiol 15, 354–359 (1986). https://doi.org/10.1007/BF00348861
Issue Date:
DOI: https://doi.org/10.1007/BF00348861